Survival of stage IV melanoma in Belgium and the Netherlands

2021 ◽  
Author(s):  
K.P.M. Suijkerbuijk ◽  
J.B.A.G. Haanen ◽  
M.J. Boers‐Sonderen ◽  
G.A.P. Hospers ◽  
C.U. Blank ◽  
...  
Keyword(s):  
The Netherlands ◽  
Stage Iv ◽  
Stage Iv Melanoma

Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma

2003 ◽  
Vol 26 (5) ◽  
pp. 432-439 ◽  
Author(s):  
A. Karolina Palucka ◽  
Madhav V. Dhodapkar ◽  
Sophie Paczesny ◽  
Susan Burkeholder ◽  
Knut M. Wittkowski ◽  
...  
Keyword(s):  
T Cell ◽  
Dendritic Cell ◽  
Single Injection ◽  
Stage Iv ◽  
Dendritic Cell Vaccine ◽  
T Cell Immunity ◽  
Cell Vaccine ◽  
Cell Immunity ◽  
Stage Iv Melanoma

A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

2008 ◽  
Vol 15 (7) ◽  
pp. 2034-2041 ◽  
Author(s):  
Heather B. Neuman ◽  
Ami Patel ◽  
Nicole Ishill ◽  
Christine Hanlon ◽  
Mary Sue Brady ◽  
...  
Keyword(s):  
Stage Iv ◽  
Staging System ◽  
Single Institution ◽  
Ajcc Staging System ◽  
Ajcc Staging ◽  
Stage Iv Melanoma

scholarly journals 300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A327-A327
Author(s):  
Lexy Adams ◽  
Robert Chick ◽  
Guy Clifton ◽  
Timothy Vreeland ◽  
Patrick McCarthy ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Stage Iv ◽  
Standard Of Care ◽  
Stage Iii ◽  
Tumor Lysate ◽  
Double Blind ◽  
Free Survival ◽  
Resected Stage ◽  
Disease Free ◽  
Stage Iv Melanoma

BackgroundThe tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is created ex vivo by loading autologous dendritic cells (DC) with yeast cell wall particles (YCWP) containing autologous tumor lysate, thus delivering tumor antigens to the DC cytoplasm via phagocytosis. TLPLDC then activates a robust T cell response against the unique antigens for each patient. The primary analysis of the prospective, randomized, multi-center, double-blind, placebo-controlled phase IIb trial in patients with resected stage III/IV melanoma showed TLPLDC improved 24-month disease-free survival (DFS) in the per-treatment (PT) analysis (patients completing the 6-month primary vaccine series). Here, we examine the secondary endpoint of 36-month DFS and overall survival (OS).MethodsPatients with resected stage III/IV melanoma were randomized 2:1 to TLPLDC vaccine or placebo (autologous DC loaded with empty YCWP). Treatments were given at 0, 1, 2, 6, 12 and 18 months. The protocol was amended to include patients receiving concurrent checkpoint inhibitors (CPIs) to follow changes in standard of care. The co-primary endpoints were 24-month DFS by intention-to-treat (IT) analysis and per-treatment (PT) analysis, with secondary endpoints including 36-month DFS and OS by ITT and PT analysis, pre-specified analysis by stage, and safety as measured by CTCAE v4.03.ResultsOverall, 103 patients received TLPLDC and 41 placebo. In PT analysis, 65 patients received TLPLDC and 32 placebo. Total adverse events (AEs), grade 3+ AEs, and serious AEs (SAEs) were similar in placebo vs TLPLDC groups, with one related SAE per treatment arm. By ITT analysis, 36-month OS was 76.2% for TLPLDC vs 70.3% for placebo (HR 0.72, p=0.437) and 36-month DFS was 35.6% vs 27.1% (HR 0.95, p=0.841). By PT analysis, 36-month DFS was improved with TLPLDC (57.5% vs 35.0%; HR 0.50, p=0.025, figure 1). This effect was even more dramatic in resected stage IV patients (36-month DFS: 60.9% vs 0%; HR 0.12, p=0.001, figure 2).ConclusionsThis phase IIb trial again demonstrates the safety of the TLPLDC vaccine, and an improved 36-month DFS in patients with resected stage III/IV melanoma who complete the primary vaccine series, particularly in the stage IV subgroup. Next, a phase III trial will evaluate the efficacy of TLPLDC vaccine as adjuvant treatment for resected stage IV melanoma, with patients randomized to receive standard of care PD-1 inhibitors + TLPLDC versus PD-1 inhibitors + placebo.Abstract 300 Figure 136-month disease free survival for patients receiving TLPLDC vs placebo by PT analysisAbstract 300 Figure 236-month disease free survival for subset of stage IV melanoma patients receiving TLPLDC vs placebo by PT analysisTrial RegistrationThis is a phase IIb clinical trial registered under NCT02301611Ethics ApprovalThis study was approved by Western IRB, protocol 20141932.

scholarly journals Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha

2018 ◽  
Vol 38 (11) ◽  
pp. 6393-6397 ◽  
Author(s):  
KALLE MATTILA ◽  
PIRITA RAANTA ◽  
VALTTERI LAHTELA ◽  
SEPPO PYRHÖNEN ◽  
ILKKA KOSKIVUO ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Combination Chemotherapy ◽  
Stage Iv ◽  
Term Survival ◽  
Long Term Survival ◽  
Melanoma Patients ◽  
Stage Iv Melanoma ◽  
Intermediate Dose

Metastasectomy for Stage IV Melanoma

2015 ◽  
Vol 24 (2) ◽  
pp. 279-298 ◽  
Author(s):  
Gary B. Deutsch ◽  
Daniel D. Kirchoff ◽  
Mark B. Faries
Keyword(s):  
Stage Iv ◽  
Stage Iv Melanoma

scholarly journals Complete Remission of Brain Metastases in Three Patients with Stage IV Melanoma Treated with BOLD and G-CSF

2005 ◽  
Vol 35 (9) ◽  
pp. 507-513 ◽  
Author(s):  
Ugo Bottoni ◽  
Paola Bonaccorsi ◽  
Valeria Devirgiliis ◽  
Vincenzo Panasiti ◽  
Riccardo Giovanni Borroni ◽  
...  
Keyword(s):  
Complete Remission ◽  
Brain Metastases ◽  
Stage Iv ◽  
Stage Iv Melanoma

scholarly journals 1044P Sequential targeted and immunotherapies in stage IV melanoma

2021 ◽  
Vol 32 ◽  
pp. S875
Author(s):  
T.M.S. Amaral ◽  
J. Nolinski ◽  
H. Niessner ◽  
T. Sinnberg ◽  
O. Seeber ◽  
...  
Keyword(s):  
Stage Iv ◽  
Stage Iv Melanoma

Metastasectomy for Stage IV Melanoma: For Whom and How Much?

2011 ◽  
Vol 20 (1) ◽  
pp. 133-144 ◽  
Author(s):  
Abigail S. Caudle ◽  
Merrick I. Ross
Keyword(s):  
Stage Iv ◽  
Stage Iv Melanoma
Sign in / Sign up

Export Citation Format

Share Document